AstraZeneca to Build Advanced ADC Manufacturing Facility in Singapore
| Aspect | Details |
|---|---|
| Company | AstraZeneca |
| Facility Type | Manufacturing facility for Antibody-Drug Conjugates (ADCs) |
| Location | Singapore |
| Focus | Production of Antibody-Drug Conjugates (ADCs), a class of cancer-fighting medications |
| Investment | Supported by the Singapore Economic Development Board |
| Purpose | Expanding global supply chain; advancing innovative cancer treatments |
| Facility Features | First end-to-end ADC production site (antibody generation to final product filling) |
| Construction Start | End of 2024 |
| Operations Start | 2029 |
| Environmental Commitment | Zero carbon emissions from the first day of operations |
| Economic Impact | Expected to create job opportunities and stimulate economic growth in Singapore's pharmaceutical and healthcare sectors |